Details for Patent: 8,993,640
Which drugs does patent 8,993,640 protect, and when does it expire?
Patent 8,993,640 protects SKYCLARYS and is included in one NDA.
This patent has sixty-seven patent family members in forty countries.
Summary for Patent: 8,993,640
| Title: | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention relates generally to the compound: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Eric Anderson, Xiaofeng Liu, Andrea Decker | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Solvias AG , Reata Pharmaceuticals Holdings LLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US13/869,833 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 8,993,640: Omaveloxolone Claims, Patent Scope, Exclusivity and Generic RiskUS Patent 8,993,640 is a core Reata Pharmaceuticals patent covering omaveloxolone, now marketed by Biogen as Skyclarys. The patent has four principal claim groups: the active compound, solid-state forms and solvates, pharmaceutical compositions, and methods for treating inflammation- or oxidative-stress-related diseases. Its broadest commercial relevance is the compound claim and the composition claim. The polymorph claims provide narrower manufacturing and formulation protection, while the method claims cover several non-Friedreich ataxia indications, including radiation-induced dermatitis and mucositis. The patent was granted on March 31, 2015. Its ordinary US patent term is expected to run into approximately 2030, subject to the controlling USPTO term calculation, terminal disclaimers, and any patent-term adjustment. Skyclarys received FDA approval on February 28, 2023, for Friedreich's ataxia in adults and adolescents aged 16 years and older. The approval created separate regulatory exclusivity that is distinct from the patent term. What drug does US Patent 8,993,640 protect?US 8,993,640 protects omaveloxolone, also known as RTA 408. The compound is an activator of nuclear factor erythroid 2-related factor 2, or Nrf2, and is intended to regulate antioxidant and anti-inflammatory pathways. The plaintext claim set supplied omits the chemical structure drawings. The patent's claim architecture, disease indications, and solid-state disclosures identify the claimed compound as omaveloxolone and its pharmaceutically acceptable salts.
Sources: US Patent No. 8,993,640; FDA, Skyclarys prescribing information; FDA Orange Book. What are the independent claims in US 8,993,640?The patent has five commercially important independent claims or independent claim categories. Claim 1: Omaveloxolone and pharmaceutically acceptable saltsClaim 1 covers the compound shown in the patent's formula and pharmaceutically acceptable salts. This is the principal composition-of-matter claim. A valid infringement case under claim 1 would generally focus on whether a competing product contains omaveloxolone or a salt within the claimed structural definition. The claim does not depend on a particular dosage form, excipient, indication, manufacturing process, or crystal form. This claim has the broadest blocking effect because it can reach:
A generic manufacturer cannot avoid a compound claim merely by changing tablet excipients or labeling the product for a different disease. It would need to avoid the claimed chemical structure, challenge validity, or obtain a license. Claims 2-18: Polymorphic forms and solvatesClaims 2 through 18 cover specific solid-state forms of the claimed compound. These claims are narrower than claim 1 and rely on analytical characteristics, including:
The solid-state claim groups are as follows:
These claims are important for manufacturing control. A commercial product may use a particular crystalline form because it has better stability, filtration, drying, dissolution, or storage characteristics. A generic developer can attempt to manufacture a different form, but it must establish that the alternative does not reproduce the claimed XRPD, DSC, Tg, or solvate characteristics. Claim 19: Pharmaceutical compositionClaim 19 covers a pharmaceutical composition containing the claim 1 compound as the active ingredient and a pharmaceutically acceptable carrier. This claim is broader than a claim limited to the marketed Skyclarys tablet because it does not recite:
The phrase "active ingredient consisting of a compound of claim 1" may limit the claim to the identified active compound rather than a combination product. The carrier limitation is conventional, but it still provides a product claim directed to pharmaceutical preparations containing omaveloxolone. Claims 20-23: Therapeutic methodsClaim 20 covers treatment of conditions associated with inflammation or oxidative stress using the composition of claim 19. The listed conditions include:
Claim 21 narrows dermatitis to radiation-induced dermatitis. Claim 22 addresses radiation- or chemotherapy-induced mucositis. Claim 23 covers reducing the duration or severity of radiation-induced oral mucositis or dermatitis by administering the composition before and/or after acute radiation treatment. These claims are method-of-use claims, not product claims. They may be relevant to a company developing omaveloxolone for oncology supportive care, radiation injury, pulmonary disease, or inflammatory disorders. They do not necessarily block a generic seeking approval solely for Friedreich's ataxia if the relevant indication is carved out and the Orange Book-listed use does not create an infringement issue. How strong is the compound claim compared with the polymorph claims?The compound claim is materially stronger from a commercial blocking perspective than the solid-state claims.
The solid-state claims could be difficult to enforce if the patent does not clearly establish the identity, stoichiometry, or reproducibility of each solvate. XRPD peak positions are also subject to instrument conditions, sample preparation, preferred orientation, humidity, and measurement error. Claims tied to a figure may raise claim-construction questions about whether the figure defines an exact pattern or merely illustrates a representative pattern. What formulations are protected by US 8,993,640?The patent protects pharmaceutical compositions containing the claimed compound and a pharmaceutically acceptable carrier. It does not, based on the supplied claims, require the commercial Skyclarys excipient system or a particular tablet design. The formulation scope can therefore reach:
The claims supplied do not expressly recite:
Those features may be addressed in later patent families or regulatory product specifications, but they are not limitations apparent from claim 19. When does omaveloxolone lose exclusivity?Omaveloxolone has separate patent and FDA exclusivity layers. Patent exclusivityUS 8,993,640 was granted in 2015 and has an ordinary term extending approximately to 2030. The exact expiration date depends on the patent's earliest effective nonprovisional or PCT filing date and any patent-term adjustment. A patent expiration date does not automatically permit unrestricted generic entry if later, independently valid patents cover the approved product, a formulation, a method of use, or a manufacturing process. Orphan-drug exclusivityFDA approved Skyclarys for Friedreich's ataxia on February 28, 2023. Orphan-drug exclusivity generally runs for seven years from approval, placing the principal regulatory exclusivity endpoint in approximately February 2030. Orphan exclusivity blocks FDA approval of the same drug for the same orphan indication, subject to statutory exceptions. It does not prevent all off-label use or approval for a different indication. New chemical entity exclusivityIf Skyclarys received five-year new chemical entity exclusivity, that period would run approximately through February 2028. NCE exclusivity restricts submission or approval timing for certain abbreviated applications, but it is separate from both the patent term and orphan exclusivity.
What is the Orange Book status of US 8,993,640?US 8,993,640 is associated with the Skyclarys patent estate and is relevant to FDA-listed patent analysis for omaveloxolone. The Orange Book must be reviewed for the exact patent number, use code, and listed expiration date because FDA listing information can distinguish between:
An Orange Book listing does not establish patent validity or infringement. It triggers the certification framework for an ANDA applicant and gives the patent holder an opportunity to bring a Hatch-Waxman action after a Paragraph IV notice. Which companies are challenging omaveloxolone patents?No publicly established Paragraph IV litigation or final settlement involving a generic omaveloxolone challenger is identified in the supplied record. The principal commercial actors are:
An ANDA applicant would likely face a Paragraph IV certification against relevant listed patents or a Paragraph III certification deferring approval until patent expiry. A section viii statement could be used to carve out a patented method of use if the generic label excludes the protected indication. What Paragraph IV risks exist?The main Paragraph IV theories would likely target different claim groups separately. Claim 1 invalidity or noninfringementA challenger could argue that:
For a true omaveloxolone product, noninfringement of claim 1 would generally be difficult if the structural formula covers the active ingredient as identified. Polymorph claim challengesThe polymorph claims may be challenged on:
A generic manufacturer may also attempt to use a form that is not among the claimed XRPD patterns. Method-of-use carve-outsClaims 20-23 are more susceptible to label-based design-around than claim 1. A generic product could seek approval for Friedreich's ataxia while omitting radiation-induced dermatitis, mucositis, and other patented uses, assuming the relevant FDA labeling and marketing conduct support a noninfringement position. Does omaveloxolone face biosimilar risk?No. Omaveloxolone is a small-molecule drug, not a biologic. A competitor would use the ANDA pathway for a chemically equivalent generic, not the biosimilar pathway under the Public Health Service Act. The relevant competitive risks are:
What licensing deals affect the patent estate?Reata developed omaveloxolone and commercialized the program before its acquisition by Biogen. Reata also had a broader strategic collaboration with AbbVie involving certain Nrf2 activator programs. That collaboration was terminated, with rights returning to Reata. Biogen's acquisition transferred control of Reata's commercial assets and patent portfolio to Biogen. The Reata-AbbVie history is relevant to chain-of-title review, but it does not by itself establish that AbbVie retains rights to US 8,993,640. Current ownership, recorded assignments, security interests, and licensing restrictions should be assessed through USPTO assignment records and the relevant transaction documents. What generic launch scenarios exist?Three launch scenarios are commercially plausible.
A product that contains omaveloxolone remains exposed to the compound and composition claims even if it uses a different crystal form. A polymorph design-around therefore may not create a complete pathway around claim 1. How does this patent compare with later omaveloxolone patents?US 8,993,640 is best understood as an early, foundational patent. Its value comes from the combination of a compound claim and supporting solid-state and method claims. Later patents in the omaveloxolone estate may provide additional protection for:
The earlier patent is more important for chemical identity. Later patents may be more important after the 2030 compound-patent horizon if they have valid terms extending beyond that date. A full freedom-to-operate review should therefore map the complete US family, Orange Book entries, continuations, divisionals, and terminal disclaimers rather than rely on US 8,993,640 alone. Key Takeaways
FAQsIs US 8,993,640 a composition-of-matter patent for omaveloxolone?Yes. Claim 1 covers the claimed omaveloxolone structure and pharmaceutically acceptable salts, making it the principal composition-of-matter claim. Can a generic use a different omaveloxolone polymorph?Possibly, but a different polymorph would not by itself avoid the compound claim or the pharmaceutical-composition claim. The alternative form would need to avoid the specific solid-state claims and any later polymorph patents. Does US 8,993,640 cover Skyclarys dosing?The supplied claims do not recite a specific Skyclarys dose or dosing schedule. Dose-specific protection may reside in other patent families. Can a generic obtain approval for Friedreich's ataxia while carving out radiation-induced mucositis?Potentially. Claims 21-23 are method-of-use claims directed to radiation-related conditions, so a section viii carve-out may be relevant if the approved labeling and commercial conduct exclude those uses. Is Biogen the current owner of the patent?Biogen acquired Reata Pharmaceuticals and its commercial assets, including the omaveloxolone program. The definitive legal owner and any encumbrances should be confirmed against the latest USPTO assignment record. References
More… ↓ |
Drugs Protected by US Patent 8,993,640
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Us | SKYCLARYS | omaveloxolone | CAPSULE;ORAL | 216718-001 | Feb 28, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,993,640
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2841445 | ⤷ Start Trial | CA 2024 00015 | Denmark | ⤷ Start Trial |
| European Patent Office | 2841445 | ⤷ Start Trial | PA2024511 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2841445 | ⤷ Start Trial | LUC00340 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2841445 | ⤷ Start Trial | 301276 | Netherlands | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
